Hyperglycemia is an expected on-target side effect of PI3Kα inhibition given the involvement of PI3Kα in glucose homeostasis regulation and occurs more frequently with a targeted compound like alpelisib compared to pan-PI3K inhibitors or to beta, gamma or delta specific PI3K inhibitors. Here, PIK3CA is linked to Hyperglycemia.